Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.39 |
| ▸ | ITGA1 | P56199 | 2/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 3/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142787 | 0.91 | MAPK1 (0.42) | MAPK1GAATRPV4ITGA1FABP4 | |
| SCHEMBL4142783 | 0.91 | MAPK1 (0.42) | MAPK1GAATRPV4ITGA1FABP4 | |
| SCHEMBL4140911 | 0.90 | MAPK1 (0.41) | MAPK1GAATRPV4ITGA1FABP4 | |
| SCHEMBL4143367 | 0.90 | MAPK1 (0.41) | MAPK1GAATRPV4ITGA1FABP4 | |
| SCHEMBL4143372 | 0.90 | MAPK1 (0.41) | MAPK1GAATRPV4ITGA1FABP4 | |
| SCHEMBL4140909 | 0.90 | MAPK1 (0.41) | MAPK1GAATRPV4ITGA1FABP4 | |
| SCHEMBL4127414 | 0.89 | MAPK1 (0.39) | MAPK1GAATRPV4ITGA1FABP4 | |
| SCHEMBL4127419 | 0.89 | MAPK1 (0.39) | MAPK1GAATRPV4ITGA1FABP4 | |
| SCHEMBL4136390 | 0.89 | MAPK1 (0.40) | MAPK1GAATRPV4ITGA1FABP4 | |
| SCHEMBL4140598 | 0.89 | MAPK1 (0.40) | MAPK1GAATRPV4ITGA1FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | MAPK1 1486/4885GAA 3715/4885TRPV4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.